Urs Albert Meyer

[vc_row][vc_column width=”1/4″]Urs Albert Meyer
[/vc_column][vc_column width=”3/4″]

Professor Urs Alber Meyer, MD, Switzerland

Urs A. Meyer went through a remarkable career as physician and scientist whose discoveries and scientific results have fundamentally contributed to clinical pharmacology and its development in the last decades.

His research has focused on “pharmacological individuality” or person-to-person variation of drug response throughout his career, from studying the drug sensitivity of the pharmacogenetic disease porphyria to the pharmacogenomics of drug disposition and its coregulationby drug interactions and environmental factors. These predictable variations in drug response are important components of individualized drug therapy or personalized and stratified medicine. Urs Meyer probably is best known for the discovery of the molecular mechanisms of several common genetic polymorphisms of drug disposition.

exc. from the nomination letter. You will find the document as a PDF download below.

[wm_tabs active=”1″ ]

[wm_item title=”Nomination Letter”]

Dear Professor Maxwell,

The Swiss Society of Clinical Pharmacology and Toxicology is happy to propose Urs Albert Meyer M.D. as nominee for the EACPT Lifetime Achievement Award in Clinical Pharmacology2017.

Urs A. Meyer went through a remarkable career as physician and scientist whose discoveries and scientific results have fundamentally contributed to clinical pharmacology and its development in the last decades. Urs Meyer’s research has focused on “pharmacological individuality” or person-to-person variation of drug response throughout his career, from studying the drug sensitivity of the pharmacogenetic disease porphyria to the pharmacogenomics of drug disposition and its coregulationby drug interactions and environmental factors. These predictable variations in drug response are important components of individualized drug therapy or personalized and stratified medicine. Urs Meyer probably is best known for the discovery of the molecular mechanisms of several common genetic polymorphisms of drug disposition.

Urs Meyer’s work has resulted in >340 publications and a H-index of 85. His scientific achievements have been recognized by numerous awards and honors including the Rawls-Palmer Award for Progress in Medicine by the American Society for Clinical Pharmacology and Therapeutics and the RT Williams Distinguished Scientific Achievement Award of the International Society for the Study of Xenobiotics – among many others. He has trained 71 graduate students and 62 postdoctoral fellows and many of his previous collaborators are now in academic positions all over the world.

The Executive Committee of the Swiss Society of Clinical Pharmacology and Toxicology would therefore highly recommend Urs. A. Meyer for this award.

With best regards,
Dr. H. Kupferschmidt, M.D., President SSCPT

23nd October 2016

view original nomination letter by SSCPT | Letter of Acceptance


[wm_item title=”Curriculum Vitae”]

Personal Details

Prof. Urs Alber Meyer, M.D.

Born: Baden, Switzerland
Citizenship: Switzerland

Homepage: http://www.ursmeyer.biozentrum.unibas.ch
Wikipedia: http://en.wikipedia.org/wiki/Urs_A._Meyer

Educational and Professional Experience
1958 – 1961 Basic Medical Sciences, University of Geneva, Switzerland
1964 Graduation from University of Zürich Medical School
1967 M.D., Doctoral thesis, University of Zürich, Switzerland
6/65 – 6/67 Research Assistant, Metabolic Unit, Department of Medicine, University of Zürich Medical School. Work was in the field of adipose tissue metabolism under the direction of E. Rudolf Froesch
7/67 – 6/68 Internship – Straight Medicine
University of California San Francisco Medical Center (UCSF)
San Francisco, California. Lloyd H. Smith, Jr., Head of the Department of Medicine.
7/68 – 6/69 Resident – Internal Medicine
University of California Hospitals, San Francisco, California.
9/69 – 9/70 United States Public Health Service Special Postdoctoral Research Fellowship in Clinical Pharmacology – Department of Medicine University of California San Francisco Medical Center, San Francisco, California. Clinical training in the Division of Clinical Pharmacology under the direction of Kenneth L. Melmon. Research in the field of drug metabolism under the direction of Harvey S. Marver and Rudi Schmid.
9/70 – 8/71 United States Public Health Service Special Postdoctoral Research Fellowship in Hepatology – Departments of Internal Medicine and of Biochemistry, University of Texas Southwestern Medical School, Dallas, Texas, USA, under the direction of Harvey S. Marver and Ronald W. Estabrook.
8/71 – 6/72 Instructor of Medicine and Pharmacology, Division of Clinical Pharmacology, Department of Medicine, University of California, Medical Center, San Francisco, USA
7/72 – 6/74 Assistant Professor of Medicine and Pharmacology. Div. of Clinical Pharma- cology, Dept. of Medicine, University of California, San Francisco, USA.
7/74 – 3/83 Chief, Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, University of Zürich Medical School, University Hospital, Zürich, Switzerland.
10/76 – 3/83 Associate Professor of Clinical Pharmacology (Extraordinarius), University of Zürich Medical School, Zürich, Switzerland.
3/83 – 7/08 Professor of Pharmacology (Ordinarius), University of Basel Medical School, and Chairman, Department of Pharmacology, Biozentrum of the University of Basel, Basel, Switzerland.
7/92 – 6/93 Visiting Professor, Department of Molecular Pharmacology, Stanford University School of Medicine, Stanford, California, USA
11/93-11/95 Acting Chairman, Biozentrum of the University of Basel, Basel, Switzerland
12/08 – Professor emeritus of Pharmacology, University of Basel
4/08-7/08 Sabbatical Professor, Office of Clinical Pharmacology, Center of Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, MD, USA
The American Society for Pharmacology and Experimental Therapeutics
Swiss Society of Clinical Pharmacology and Toxicology (SSCPT), President of
the Section Clinical Pharmacology (1986-1988)
Drug Metabolism Section, IUPHAR
International Society for the Study of Xenobiotics (ISSX)
Gesellschaft für Fortschritte in der Inneren Medizin (Ludwig-Heilmeyer-Gesellschaft)
European Society of Pharmacogenomics and Personalised Therapy (ESPT) The Swiss Group of Pharmacogenomics and Personalised Therapy (SPT)
1971 – 1974 Faculty Development Award in Clinical Pharmacology, Pharmaceutical Manufacturers Association Foundation
1974 Cloetta-Award 1974 for Medical Research
1978 Award of the Anita Saurer Foundation, 1978
1990 William D. Stubenboard Visiting Professorships, Cornell Medical Center, New York
1991 Rawls-Palmer Award for Progress in Medicine (with Frank J. Gonzalez) American Society for Clinicical Pharmacology and Therapeutics
1993 Featured on Cover Page of Cancer Research for work on Acetyltransferase Genes and Cancer
1993 The Sterling Drug Visiting Professor, University of Oregon School of Medicine, Portland, Oregon.
1993 Elected Member, Academia Europaea
1994 The Ariëns Lecture of the Dutch Pharmacological Soc., Leiden
1994 The Sandoz Lecture in Clinical Pharmacology, USU, Bethesda, MD, USA
1997 Council, Academia Europaea
1998 Medeval Distinguished Lecturer, University of Manchester, U.K.
1999 Werner Kalow Annual Award Lectureship in Pharmacogenetics, Toronto, Canada
2000 Ad hoc member of the Council of the NIGMS, NIH, Bethesda, USA
2001 Elected to membership, Swiss Academy of Medical Sciences
2001 Listed on ISI’s Highly Cited Researcher’s database
2002 External Scientific Panel-NIH Pharmacogenetics Research Network
2003 Vice-President, Academia Europaea
2004 Robert Pfleger-Forschungspreis 2004
2004 RT Williams Distinguished Scientific Achievement Award” International Society for the Study of Xenobiotics” ISSX in Bethesda, MD, USA
1981 – 1991 National Research Council, Swiss National Science Foundation
1988 – 1992 Advisory Board, Robert Bosch Stiftung, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
1989 – 1991 President, Clinical Section, Division of Biology and Medicine, Swiss National Science Foundation
1989 – 1996 Member of the Board of Trustees, Sandoz Foundation for Gerontological Research, Basel.
1994 – 1998 Scientific Council, International Agency for Research on Cancer, WHO, Lyon, France
1997 – 2000 Swiss Board of Consultants, Basel Institute for Immunology
2000 – Co-editor Pharmacogenomics, Faculty 1000
2010 – 2011 President, International Society for the Study of Xenobiotics
2012 – 2015 President, European Center for Pharmaceutical Medicine Foundation

download CV | download extended descriptive CV

[wm_item title=”Publications”]

  1. Insel PA, Amara SG, Blaschke TF, Meyer UA. 2016. Introduction to the Theme „Cancer Pharmacology“.
    Annu Rev Pharmacol Toxicol 56:19-22.
  2. Kalman LV et al (46 authors). 2016. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther 99(2): 172-185.
  3. Shahabi P, Siest G, Meyer UA, Visvikis-Siest S. 2014. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. Pharmacol Ther 144(2): 134-161.
  4. Meyer UA, Zanger UM, Schwab M. 2013. Omics and drug response. Annu Rev Pharmacol Toxicol 53:475-502 Meyer UA. 2012. Personalized medicine: a personal view. Clin Pharmacol Ther 91:373-5
    Meyer UA. 2012. Cytochrome P450 enzymes. Drug Metabol Drug Interact 27:1-2
  5. Handschin C, Meyer UA. 2012. Warum reagiert mein Patient anders auf dieses Medikament? Pharmakogenomik und Personalisierte Medizin in der Praxis. Schweiz Med Forum 12:425-33
  6. Meyer UA. 2011. Welcome to the Journal of Personalized Medicine. J Pers Med 1: 1-4.
  7. Tamasi V, Juvan P, Beer M, Rozman D, Meyer UA. 2009. Transcriptional activation of PPARalpha by phenobarbital in the absence of CAR and PXR. Mol Pharm 6:1573-81
  8. Rezen T, Tamasi V, Lovgren-Sandblom A, Bjorkhem I, Meyer UA, Rozman D. 2009. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. BMC Genomics 10:384
  9. Kim MJ, Huang SM, Meyer UA, Rahman A, Lesko LJ. 2009. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol 49:138-46
  10. Roth A, Looser R, Kaufmann M, Meyer UA. 2008. Sterol regulatory element binding protein 1 interacts with pregnane X receptor and constitutive androstane receptor and represses their target genes. Pharmacogenet Genomics 18:325-37
  11. Roth A, Looser R, Kaufmann M, Blattler SM, Rencurel F, et al. 2008. Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression.
    Mol Pharmacol 73:1282-9
  12. Rezen T, Juvan P, Fon Tacer K, Kuzman D, Roth A, et al. 2008. The Sterolgene v0 cDNA microarray: a systemic approach to studies of cholesterol homeostasis and drug metabolism. BMC Genomics 9:76
  13. Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, et al. 2007. Sulfonylureas and Glinides Exhibit Peroxisome Proliferator-Activated Receptor {gamma} Activity: A Combined Virtual Screening and Biological Assay Approach. Mol Pharmacol 71:398-406
  14. Peyer AK, Jung D, Beer M, Gnerre C, Keogh A, et al. 2007. Regulation of human liver delta-aminolevulinic acid synthase by bile acids. Hepatology 46:1960-70
  15. Oscarson M, Burk O, Winter S, Schwab M, Wolbold R, et al. 2007. Effects of Rifampicin on global gene expression in human small intestine. Pharmacogenetics and Genomics 17:907-18
  16. Orolin J, Vecera R, Jung D, Meyer UA, Skottova N, Anzenbacher P. 2007. Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha. Xenobiotica 37:725-35
    Meyer UA. 2007. Genes and the individual response to treatment. In Treating Individuals, ed. P Rothwell. Oxford: Elsevier Ltd. pp 151-68
  17. Meyer UA. 2007. Endo-xenobiotic crosstalk and the regulation of cytochromes P450. Drug Metab Rev 39:639-46
  18. Köhalmy K, Tamasi V, Kobori L, Sarvary E, Pascussi J-M, et al. 2007. Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab. Disp. 35:1495-501
  19. Blattler SM, Rencurel F, Kaufmann MR, Meyer UA. 2007. In the regulation of cytochrome P450 genes, phenobarbital targets LKB1 for necessary activation of AMP-activated protein kinase. Proc Natl Acad Sci U S A 104:1045-50
  20. Rencurel F, Foretz M, Kaufmann MR, Stroka D, Looser R, et al. 2006. Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Mol Pharmacol 70:1925-34
  21. Podvinec M, Meyer UA. 2006. Prediction of cis-regulatory elements for drug-activated transcription factors in the regulation of drug-metabolising enzymes and drug transporters. Expert Opin Drug Metab Toxicol 2:367-79
  22. Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA. 2006. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther 80:440-56
  23. Jung D, Mangelsdorf DJ, Meyer UA. 2006. Pregnane X receptor is a target of farnesoid X receptor. J Biol Chem
  24. Meyer UA, Flockhart DA. 2005. Clincal Perspectives. In Pharmacogenomics, ed. W Kalow, Meyer,UA.,Tyndale RF. New York: Taylor & Francis.pp 247-63
  25. Meyer UA, Blättler S, Gnerre C, Oscarson M, Peyer A-K, et al. 2005. In vitro, in vivo, and in silico approaches to predict induction of drug metabolism. In Pharmacokinetic profiling in drug research: biological, physiocochemical, and computational strategies: Helvetica Chimica Acta. pp. 93-103.
  26. Meyer RP, Lindberg RL, Hoffmann F, Meyer UA. 2005. Cytosolic persistence of mouse brain CYP1A1 in chronic heme deficiency. J Biol Chem 386:1157-64
  27. Kalow W, Meyer UA,Tyndale RF (eds), 2005. Pharmacogenomics. New York: Taylor & Francis.
  28. Handschin C, Meyer UA. 2005. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 433:387-96
  29. Handschin C, Lin J, Rhee J, Peyer AK, Chin S, et al. 2005. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 122:505-15
  30. Handschin C, Gnerre C, Fraser DJ, Martinez-Jimenez C, Jover R, Meyer UA. 2005. Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys 434:75-85
  31. Haberl M, Anwald B, Klein K, Weil R, Fuss C, et al. 2005. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 15:609-24
  32. Gnerre C, Schuster GU, Roth A, Handschin C, Johansson L, et al. 2005. LXR deficiency and cholesterol feeding affect expression and phenobarbital mediated induction of cytochromes P450 in mouse liver. J Lipid Res 46:1633-42 Podvinec M, Handschin C, Looser R, Meyer UA. 2004. Identification of the xenosensors regulating human 5- aminolevulinate synthase. Proc. Natl. Acad. Sci. U S A 101:9127-32
  33. Meyer UA. 2004. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 5:669-76 Handschin C, Meyer UA. PXR and CAR: More than meets the eye. Proc. 15th Int. Symposium on Microsomes and Drug Oxidations, Mainz, Germany, 2004: Medimond, Pianoro, Italy..
  34. Handschin C, Blaettler S, Roth A, Looser R, Oscarson M, et al. 2004. The evolution of drug-activated nuclear receptors: one ancestral gene diverged into two xenosensor genes in mammals. Nucl Recept 2:7
  35. Gnerre C, Blaettler S, Kaufmann MR, Looser R, Meyer UA. 2004. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14:635-45
  36. Baader M, Meyer UA. 2004. Cytochrome P450 (CYP) monooxygenase superfamily. xPharm
  37. Baader M, Meyer UA. 2004. Cytochrome P450 (CYP) monooxygenase 2C9. xPharm
  38. Baader M, Meyer UA. 2004. Cytochrome P450 (CYP) monooxygenase 2B6. xPharm
  39. Baader M, Meyer UA. 2004. Cytochrome P450 (CYP) monooxygenase 2C19. xPharm
  40. Baader M, Meyer UA. 2004. Cytochrome P450 (CYP) monooxygenase 3A4-5. xPharm
  41. Baader M, Meyer UA. 2004. Cytochrome P450 (CYP) monooxygenase 1A1-2. xPharm
  42. Baader M, Meyer UA. 2004. Cytochrome P450 (CYP) monooxygenase 2D6. xPharm
  43. Sanyal S, Handschin C, Podvinec M, Song KH, Kim HJ, et al. 2003. Molecular cloning and characterization of chicken orphan nuclear receptor cTR2. Gen Comp Endocrinol 132:474-84
  44. Meyer UA. 2003. Genetic polymorphisms and induction/repression of drug metabolism as major determinants of interindividual variation in drug response. J UOEH 25:87-96
  45. Handschin C, Podvinec M, Meyer U. 2003. In silico approaches, and in vitro and in vivo experiments to predict induction of drug metabolism. Drug News Perspect 16:423-34
  46. Handschin C, Meyer UA. 2003. Induction of Drug Metabolism: the role of nuclear receptors. Pharmacol Rev 55:649-73
  47. Handschin C, Meyer UA. 2003. The molecular mechanism of induction of cytochromes P450 by drugs and other xenobiotics. Nova Acta Leopoldina NF 87 Nr. 329:205-11
  48. Fried R, Meyer UA. 2003. Akute hepatische porphyrie (akut intermittierende Porphyrie, hereditäre Koproporphyrie, Porphyria variagata. In Internistische Notfälle, ed. NE Gyr, RA Schoenenberger, WE Haefeli: pp.149-51. Stuttgart: Thieme
  49. Fraser DJ, Zumsteg A, Meyer UA. 2003. Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase gene. J Biol Chem 278:39392-401
  50. van Giersbergen PLM, Gnerre C, Treiber A, Dingemanse J, Meyer UA. 2002. Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. European J Pharmacol 450:115-21
  51. Podvinec M, Kaufmann MR, Handschin C, Meyer UA. 2002. NUBIScan, an in-silico approach for prediction of nuclear receptor response elements. Mol Endocrin 16:1269-79
  52. Ourlin JC, Handschin C, Kaufmann M, Meyer UA. 2002. A Link between Cholesterol Levels and Phenobarbital Induction of Cytochromes P450. Biochem Biophys Res Commun 291:378-84
  53. Narimatsu S, Takemi C, Tsuzuki D, Kataoka H, Yamamoto S, et al. 2002. Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes. J Pharmacol Exp Ther 303:172-8
  54. Meyer UA, Gut J. 2002. Genomics and the prediction of xenobiotic toxicity. Toxicology 181-182:463-6
  55. Meyer UA. 2002. Introduction to pharmacogenomics: promises, opportunities, and limitations. In Pharmacogenomics, ed. J Licinio, M Wong:1-8. Weinheim (Germany): Wiley-VCH. pp. 1-8
  56. Meyer RP, Podvinec M, Meyer UA. 2002. Cytochrome P450 CYP1A1 accumulates in the cytosol of kidney and brain and is activated by heme. Mol Pharmacol 62:1061-7.
  57. Kalow W, Meyer UA, Tyndale RF, eds. 2002. Pharmacogenetics. Tokyo: Technomics, Inc. (Japanese edition)
  58. Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, et al. 2002. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 122:1954-66
  59. Handschin C, Podvinec M, Amherd R, Looser R, Ourlin JC, Meyer UA. 2002. Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450. J Biol Chem 277:29561-7
  60. Fraser DJ, Podvinec M, Kaufmann MR, Meyer UA. 2002. Drugs mediate the transcriptional activation of the 5- aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR). J Biol Chem 277:34717-26
  61. Baader M, Gnerre C, Stegeman JJ, Meyer UA. 2002. Transcriptional Activation of Cytochrome P450 CYP2C45 by Drugs Is Mediated by the Chicken Xenobiotic Receptor (CXR) Interacting with a Phenobarbital Response Enhancer Unit. J Biol Chem 277:15647-53
  62. Wong JMY, Harper pA, Meyer UA, Bock KW, Mörike K, et al. 2001. Ethnic variability in the allelic distributionof human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. Pharmacogenetics 11:85-94
  63. Schuurmans MM, Hoffmann F, Lindberg R, Meyer UA. 2001. Zinc mesoporphyrin represses induced hepatic 5- aminolevulinic acid synthase and reduces heme oxygenase activity in a mouse model of acute hepatic porphyria. Hepatology 33:1217-22
  64. Meyer UA. 2001. Pharmakogenomik. Medgen 13:246-8
  65. Meyer UA. 2001. Pharmacogenetics – Clinical Viewpoints. In Pharmacogenomics, ed. W Kalow, UA Meyer, RF Tyndale. New York, Basel: Marcel Dekker, Inc. pp 135-50
  66. Kalow W, Meyer UA, Tyndale RF. 2001. Pharmacogenomics. New York, Basel: Marcel Dekker.
  67. Handschin C, Podvinec M, Stöckli J, Hoffmann K, Meyer UA. 2001. Conservation of signaling pathways of xenobiotic-sensing orphan nuclear receptors, chicken xenobiotic receptor, constitutive androstane receptor, and pregnane X receptor, from birds tu humans. Mol Endocrinol 15:1571-85
  68. Handschin C, Podvinec M, Looser R, Amherd R, Meyer UA. 2001. Multiple enhancer units mediate drug-induction of CYP2H1 by xenobiotic-sensing orphan nuclear receptor Chicken Xenobiotic Receptor. Mol Pharm 60:681-9
  69. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, et al. 2001. Genomic organization of the human CYP3a locus: identificationof a new, inducible CYP3A gene. Pharmacogenetics 11:111-21
  70. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, et al. 2001. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-58
  71. Ourlin JC, Baader M, Fraser D, Halpert JR, Meyer UA. 2000. Cloning and functional expression of a first inducible avian cytochrome P450 of the CYP3A subfamily (CYP3A37). Arch Biochem Biophys 373:375-84
  72. Meyer UA. 2000. Pharmacogenetics. In Melmon & Morelli’s Clinical Pharmacology, ed. GS Carruthers, BB Hoffman, KL Melmon, DW Nierenberg, 4th edition:1179-205. New York: McGraw-Hill. Number of 1179-205 pp.
  73. Meyer UA. 2000. Drugs and toxins – drug handling. In Liver Cirrhosis and its Development, ed. JL Boyer: Kluwer Academic Publishers: pp 236-41
  74. Meyer UA. 2000. Pharmacogenetics and adverse drug reactions. Lancet 356:1667-71
  75. Handschin C, Podvinec M, Meyer UA. 2000. CXR, a chicken xenobiotic-sensing orphan nuclear receptor, is related to both mammalian pregnane X receptor (PXR) and constitutive androstane receptor (CAR). Proc Natl Acad Sci U S A 97:10769-74
  76. Handschin C, Meyer UA. 2000. A conserved nuclear receptor consensus sequence (DR-4) mediates transcriptional activation of the chicken CYP2H1 gene by phenobarbital in a hepatoma cell line. J Biol Chem 275:13362-9
  77. Fried R, Meyer UA. 2000. Porphyrien. In Klinische Gastroenterologie und Stoffwechsel, ed. G Adler et al. (eds). Berlin: Springer-Verlag. pp 837-45
  78. Amherd R, Hintermann E, Walz D, Affolter M, Meyer UA. 2000. Purification, cloning, and characterization of a second arylalkylamine N-acetyltransferase from drosophila melanogaster. DNA Cell Biol 19:697-705
  79. Meyer UA, Hoffmann K. 1999. Phenobarbital-mediated changes in gene expression in the liver. Drug Metab Rev 31:365- 79
  80. Metry J-M, Meyer UA. 1999. Drug regimen compliance. Issues in clincial trials and patient management. Chichester, UK; Jophn Wiley & Sons.
  81. Lindberg RLP, Martini R, Baumgartner M, Erne B, Borg J, et al. 1999. Motor neoropathy in porphobilinogen deaminase- deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest 103:1127-34
  82. Haller L, Sossouhounto R, Coulibaly IM, Dosso M, Kone M, et al. 1999. Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: a controlled clinical trial. Chemotherapy 45:452-65
  83. Schuurmans M, Meyer UA. 1998. Akute hepatische Porphyrie (akut intermittierende Porphyrie, hereditäre Koproporphyrie, Porphyria variegata). In Internistische Notfälle, ed. NE Gyr, RA Schoenenberger, WE Haefeli:.Stuttgart: Georg Thieme Verlag. pp 137-49
  84. Rothen J-P, Haefeli WE, Meyer UA, Todesco L, Wenk M. 1998. Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo. Pharmacogenetics 8:553-9
  85. Meyer UA, Schuurmans MM, Lindberg RLP. 1998. Acute Porphyrias: pathogenesis of neurological manifestations. Sem Liver Dis 18:43-52
  86. Meyer UA, Lindberg R. 1998. Eine transgene Maus mit der Krankheit Porphyrie. Uni Nova:31-4
  87. Meyer UA. 1998. Medically relevant genetic variation of drug effects. In Evolution in Health and Disease, ed. S Stearns: Oxford University Press. pp 41-49
  88. Meyer UA. 1998. Polymorphisms of genes of toxicological significance. In Molecular Biology in Toxicology, ed. A. Puga, KB Wallace: Washington: Taylor and Francis. pp 63-71
  89. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, et al. 1998. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 286:1490-5.
  90. Brodbeck D, Amherd R, Callaerts P, Hintermann E, Meyer UA, Affolter M. 1998. Molecular and biochemical characterization of the aaNAT1 (Dat) Locus in Drosophila melanogaster: differential expression of two gene products. DNA Cell Biol 17:621-33
  91. Scott RJ, Taeschner W, Heinimann K, Muller H, Dobbie Z, et al. 1997. Association of extracolonic manifestations of familial adenomatous polyposis with acetylation phenotype in a large FAP kindred. Eur J Hum Genet 5:43-9.
  92. Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. 1997. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 7:1-10.
  93. Meyer UA, Zanger UM. 1997. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269-96
  94. Marez D, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, et al. 1997. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution.
    Pharmacogenetics 7:193-202
  95. Früh FW, Zanger UM, Meyer UA. 1997. Extent and character of phenobarbital-mediated changes in gene expression in liver. Mol Pharmacol 51:363-9
  96. Meyer UA, Amrein R, Balant LP, Bertilsson L, Eichelbaum M, et al. 1996. Antidepressants and drug metabolising enzymes – expert group report. Acta Psych Scand 93:71-9
  97. Meyer UA. 1996. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 8:S21-5
  98. Meyer UA. 1996. Vererbte Unterschiede in der Arzneimittelwirkung: Konsequenzen für die Arzneimitteltherapie. In
    Grundlagen der Arzneimitteltherapie. Basel: Documed.
  99. Meyer UA. 1996. Overview of enzymes of drug metabolism. J. Pharmacokinet. and Biop. 24:449-59
  100. Meyer UA. 1996. Interaction of proton pump inhibitors with cytochromes P450: Consequences for drug interactions. Yale J Biol Med 69:203-9
  101. Lindberg RLP, Porcher C, Grandchamp B, Ledermann B, Bürki K, Brandner S, Aguzzi A and Meyer UA. 1996. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nature Genet 12:195-9 Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, et al. 1996. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 60:62-7
  102. Jover R, Lindberg RLP, Meyer UA. 1996. Role of heme in cytochrome P450 transcription and function in mice treated with lead acetate. Mol Pharmacol 50:474-81
  103. Jover R, Hoffmann K, Meyer UA. 1996. Induction of 5-aminolevulinate synthase by drugs is independent of increased apocytochrome P450 synthesis. Biochem Biophys Res Comm 226:152-7
  104. Hintermann E, Grieder NC, Amherd R, Brodbeck D, Meyer UA. 1996. Cloning of an arylalkylamine N-acetyltransferase (aaNAT1) from Drosophila melanogaster expressed in the nervous system and the gut. Proc Natl Acad Sci USA 93:12315- 20
  105. Ha HR, Candinas R, Stieger B, Meyer UA, Follath F. 1996. Interaction between amiodarone and lidocaine. J Cardiovasc Pharmacol 28:533-9
  106. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, et al. 1996. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics: 159-76
  107. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, et al. 1996. Nomenclature for human CYP2D6 alleles.
    Pharmacogenetics 6:193-201
  108. Bont A, Steck AJ, Meyer UA. 1996. Die akuten hepatischen Porphyrien und ihre neurologischen Syndrome. Schweiz Med Wschr 126:3-14
  109. Agundez JA, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, et al. 1996. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 6:501-12
  110. Vatsis KP, Wendell WW, Bell DA, Dupret J-M, Price Evans DA, et al. 1995. Nomenclature for N-acetyltransferases.
    Pharmacogenetics 5:1-17
  111. Meyer UA, Gonzalez FJ, Guengerich FP, McManus ME, Okuda K-I. 1995. Human cytochromes P450: regulation and functional variability. In Pharmacological Sciences: Perspectives for Research and Therapy in the late 1990s, ed. AC
  112. Cuello, B Collier: Boston: Birkhäuser-Verlag. pp 153-9
  113. Meyer UA. 1995. The future of drug metabolism research. In European cooperation in the field of scientific and technical research Cost B1 conference on variability and specific in drug metabolism, ed. G Alvan, LP Balant, PR Bechtel, AR
  114. Boobis, LF Gram, et al:. Luxembourg: Office for Official Publ. of the European Communities. pp 303-7
  115. Meyer UA. 1995. Molecular genetics of the acetyltransferases. In Advances in Drug Metabolism in Man, ed. GM Pacifici, GN Fracchia:. Luxembourg: Office for Official Publ. of the Europ. Comm. pp 589-606
  116. Kempf AC, Zanger UM, Meyer UA. 1995. Truncated human P450 2D6: expression in Escherichia coli, Ni2-chelate affinity purification, and characterizationof solubility and aggregation. Arch Biochem Biophys 321:277-88
  117. Hintermann E, Jenö P, Meyer UA. 1995. Isolation and characterization of an arylalkylamine N-acetyltransferase from
    Drosophila melanogaster. FEBS Lett 375:148-50
  118. Daly AK, Eichelbaum M, Idle JR, Ingelman-Sundberg M, Meyer UA, et al. 1995. Progress on CYP2D6 allele nomenclature. In European cooperation in the field of scientific and technical research Cost B1 conference on variability and specificity in drug metabolism, ed. G Alvan: Luxembourg: Office for Official Publ. of the Europ. Comm. pp 589-606 Brosen K, de Morais SMF, Meyer UA, Goldstein JA. 1995. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 5:312-17
  119. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, et al. 1995. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 5:373- 84
  120. Broly F, Marez D, Lo Guidice JM, Sabbagh N, Legrand M, et al. 1995. A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum Genet 96:601-03
  121. Probst MR, Beer M, Beer D, Jeno P, Meyer UA, Gasser R. 1994. Human liver arylacetamide deacetylase. Molecular cloning of a novel esterase involved in the metabolic activation of arylamine carcinogens with high sequence similarity to hormone-sensitive lipase. J Biol Chem 269:21650-6
  122. Meyer UA. 1994. Commentary. Pharmacogenetics: The slow, the rapid, and the ultrarapid. Proc Natl Acad Sci USA
  123. Meyer UA. 1994. Polymorphisms of cytochrome P450 CYP2D6 as risk factor in carcinogenesis. In Cytochrome P450, Biochemistry, Biophysics and Molecular Biology, ed. MC Lechner. Proceedings of the Internat. Conf., John Libbey. pp 163-71
  124. Meyer UA. 1994. The molecular basis of genetic polymorphisms of drug metabolism. J. Pharm. Pharmacol. 46:409-15 Meyer UA. 1994. Polymorphism of human acetyltransferases. Environmental Health Perspectives 102, Suppl. 6:213-6 Meyer UA. 1994. Porphyrie. In Hadorn – Lehrbuch der Therapie, ed. T Hess: Bern, Göttingen: Hans Huber. pp 486-7
    Meyer UA. 1994. Cytochrome P450 in human drug metabolism: how much is predictable? In Assessment of the use of single cytochrome P450 enzymes in drug research, ed. MR Waterman, M Hildebrand: Berlin, Heidelberg, New York:
    Springer Verlag .pp 43-56
  125. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. 1994. The major defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-22
  126. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. 1994. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-98
  127. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, et al. 1993. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 289:533-8
  128. Rothman N, Hayes RB, Bi W, Caporaso N, Broly F, et al. 1993. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 3:250-5
  129. Meyer UA, Blum M, Grant D, Heim M, Broly F. 1993. Acetylation pharmacogenetics. In Human Drug Metabolism. From Molecular Biology to Man, ed. EH Jeffery:117-23. Boca Raton, Ann Arbor, London: CRC Press. pp 117-23
  130. Meyer UA. 1993. Drug metabolism in health and disease. In Extrahepatic Manifestations in Liver Diseases, ed. W Gerok, R Schmid, L. Bianchi, K.P. Maier:Dordrecht, Boston, London: Academic Publ. pp 285-93
  131. Kerdar RS, Fasshauer I, Probst M, Blum M, Meyer UA, and Wild D. 1993. 32P-Postlabelling studies on the DNA adducts of the food mutagens/carcinogens IQ and PHIP-adduct formation in a chemical system, and by rat and human metabolism. In Postlabelling Methods for the Detection of DNA Adducts, ed. DH Phillips, M Castegnaro, H Bartsch. Lyon: IARC Scientific Publ. No. 124, Internat. Agency for Research on Cancer. Hayes RB, Bi W, Rothman N, Broly F, Caproaso N, et al. 1993. N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. . Carcinogenesis 14:675-78
  132. Broly F, Meyer UA. 1993. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 3:123-30
  133. Andersson T, Miners JO, Veronees ME, Tassaneeyakul W, Tassaneeyakul W, et al. 1993. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521-30
  134. Probst MR, Blum M, Fasshauer I, D’Orazio D, Meyer UA, Wild D. 1992. The role of the human acetylation polymorphism in the metabolic activation of the food carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ). Carcinogenesis 13:1713-7
  135. Meyer UA, Skoda RC, U.M. Z, Heim M, and Broly F. 1992. The genetic polymorphism of debrisoquine/sparteine metabolism – molecular mechanism. In Pharmacogenetics of Drug Metabolism, ed. W Kalow: New York, Oxford: Pergamon Press. pp 609-23 pp.
  136. Drugs in special patient groups: clinical importance of genetics in drug effects. In Clinical Pharmacology: Basic Principles of Therapeutics., ed. KF Melmon, HF Morelli: New York: McGraw-Hill. pp 875-94
  137. Heim MH, Meyer UA. 1992. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6.
    Genomics 14:49-58
  138. Grant DM, Blum M, Meyer UA. 1992. Polymorphisms of N-acetyltransferase genes. Xenobiotica 22:1073-81
  139. Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H. 1992. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 43:399-03
  140. Tyndale RF, Aoyama T, Broly F, Matsunaga T, Inaba T, et al. 1991. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys 281: possible association with the poor metabolizer phenotype. . Pharmacogenetics 1:26- 32
  141. Probst MR, Jenoe P, and Meyer UA. 1991. Purification and characterization of a human liver arylacetamide deacetylase.
    Biochem Biophys Res Comm 177:453-9
  142. Meyer UA. 1991. Porphyrias. In Harrison’s Principles of Internal Medicine, ed. JD Wilson, KJ Isselbacher: New York: McGraw-Hill Book Company. pp 1829-34
    Meyer UA. 1991. Genotype or phenotype: the definition of a pharmacogenetic polymorphism. Pharmacogenetics 1:66-7 Meyer UA. 1991. Interindividuelle Unterschiede in der Reaktion gegenüber Arzneimitteln und Giften. Therap Rundsch
  143. Johansson I, Yue QY, Dahl ML, Heim M, Sawe J, et al. 1991. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 40:553-56
  144. Heim MH, Blum M, Beer M, Meyer UA. 1991. Acetylation of serotonin in the rabbit pineal gland: an N-acetyltransferase with properties distinct from NAT1 and NAT2 is responsible. J Neurochem 57:1095-9
  145. Heim MH, Beer M, Meyer UA. 1991. Sequence of a human pseudogene of cytochrome P450 CYP2D6, CYP2D7AP. EMBL data library
  146. Heim MH, Beer M, Meyer UA. 1991. Sequence of a human pseudogene of cytochrome P450 CYP2D6, CYP2D7BP. EMBL data library
  147. Heim M, Meyer UA. 1991. Genetic polymorphism of debrisoquine oxidation: analysis of mutant alleles of CYP2D6 by restriction fragment analysis and by allele specific amplification. Methods in Enzymology 206:173-83
  148. Grant DM, Beer M, Blum M, Meyer UA. 1991. Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39:184-91
  149. Gonzalez FJ, Meyer UA. 1991. Molecular genetics of the debrisoquin-sparteine polymorphism. The Rawls-Palmer Progress in Medicine Award Lecture. Clin Pharmacol Ther 50:233-8
  150. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, and Meyer UA. 1991. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymprhism. Am J Hum Genet 48:943-50
  151. Furuya H, Meyer UA, Gelboin HV, Gonzalez FJ. 1991. Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA. Mol Pharmacol 40:375-82
  152. Eugster HP, Sengstag C, Hinnen A, Meyer UA, Wurgler FE. 1991. Heterologous expression of human microsomal epoxide hydrolase in Saccharomyces cerevisiae. Study of the valpromide-carbamazepine epoxide interaction. Biochem Pharmacol 42:1367-72
  153. Brosen K, Zeugin T, Meyer UA. 1991. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 49:609-17
  154. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. 1991. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-58
  155. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. 1991. Molecular mechanism of slow acetylation in man. Proc Natl Acad Sci USA 88:5237-4
  156. Zeugin TB, Brosen K, Meyer UA. 1990. Determination of imipramine and seven of its metabolites in human liver microsomes by a high-performance liquid chromatographic method. Anal Biochem 189:99-102
  157. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. 1990. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442-7
  158. Nef P, Larabee TM, Kagimoto K, Meyer UA. 1990. Olfactory-specific cytochrome P-450 (P-450olf1; IIG1). Gene structure and developmental regulation. J Biol Chem 265:2903-7
  159. Mortimer O, Persson K, Ladona MG, Spalding D, Zanger UM, et al. 1990. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther 47:27-35
  160. Meyer UA, Zanger UM, Skoda RC, Grant D, Blum M. 1990. Genetic polymorphisms of drug metabolism. Prog Liver Dis
  161. Meyer UA, Skoda RC, Zanger UM. 1990. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacol Ther 46:297-308
  162. Meyer UA. 1990. Gentechnologie in den Neunziger Jahren – Neue Möglichkeiten – neue Problempotentiale. Der Basler Arzt:1-2 Meyer UA. 1990. Molecular genetics and the future of pharmacogenetics. Pharmacol Ther 46:349-55
  163. Meyer UA. 1990. Genetic polymorphisms of drug metabolism. In Advances in Drug Research, ed. B Testa, vol 19. London: Academic Press. pp 197-241
  164. Meyer UA. 1990. Genetic polymorphisms of drug metabolizing enzymes: Molecular mechanisms. Proc. European Consensus Conference on Pharmacogenetics, COST B1, Luxembourg, Commission of the European Communities. pp 7- 14
  165. Meyer UA. 1990. Genetic polymorphisms of drug metabolizing enzymes: Molecular mechanisms. Acta Pharmaceut Jugoslavica 40:491-9
  166. Meyer UA. 1990. Genetic polymorphisms of drug metabolism. Fundam Clin Pharmacol 4:595-615
  167. Meyer JW, Woggon B, Baumann P, Meyer UA. 1990. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 39:613-4
  168. Matsunaga E, Zeugin T, Zanger UM, Aoyama T, Meyer UA, Gonzalez FJ. 1990. Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation. J Biol Chem 265:17197-01
  169. Marti U, Hauri HP, Meyer UA. 1990. Induction of cytochrome P450 by phenobarbital in rat liver visualized by monoclonal antibody immunoelectron microscopy in situ. Eur J Cell Biol 52:193-200
  170. Manns M, Zanger U, Gerken G, Sullivan KF, Meyer zum Buschenfelde KH, et al. 1990. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology 12:127-32
  171. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. 1990. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-14
  172. Heim M, and Meyer UA. 1990. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification.
    Lancet 336:529-32
  173. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ. 1990. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934—-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 47:994-1001
  174. Haefeli WE, Bargetzi M, Follath F, Meyer UA. 1990. Potent inhibition of cytochrome P450IID6 by flecainide in vitro and in vivo. J Cardiovasc Pharmacol 15:776-9
  175. Gubler JG, Bargetzi MJ, Meyer UA. 1990. Primary liver carcinoma in two sisters with acute intermittent porphyria. Am J Med 89:540-1
  176. Grant DM, Mörike K, Eichelbaum M, Meyer UA. 1990. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 85:968-72
  177. Eugster HP, Sengstag C, Meyer UA, Hinnen A, Wurgler FE. 1990. Constitutive and inducible expression of human cytochrome P450IA1 in yeast Saccharomyces cerevisiae: an alternative enzyme source for in vitro studies. Biochem Biophys Res Commun 172:737-44
  178. Blum M, Heim M, and Meyer UA. 1990. Nucleotide sequence of rabbit NAT2 encoding polymorphic liver arylamine N- acetyltransferase (NAT). Nucl Acids Res 18:5295 Blum M, Heim M, and Meyer UA. 1990. Nucleotide sequence of rabbit NAT1 encoding monomorphic arylamine N- acetyltransferase. Nucl Acids Res 18:5287
  179. Blum M, Grant DM, McBride W, Heim M, Meyer UA. 1990. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization, and functional expression. DNA Cell Biol 9:193-203
  180. Blum M, Grant DM, Demierre A, and Meyer UA. Genetic polymorphism of rabbit and human N-acetyltransferase: Molecular Mechanisms . Proc. UCLA Symposia on Molecular and Cellular Biology, 1990, 126:61-70
  181. Zanger UM, Meyer UA. 1989. Absent decreased, or variant P450db1 in livers with poor capacity for debrisoquine metabolism. In Cytochrome P450: Biochemistry and Biophysics, ed. I Schuster. London: Taylor and Francis.pp 568-71
  182. Yamano S, Nhamburo PT, Aoyama T, Meyer UA, Inaba T, et al. 1989. cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: dentification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 28:7340-8
  183. Relling MV, Evans WE, Fonne-Pfister R, Meyer UA. 1989. Anticancer drugs as itnhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res 49:68-71
  184. Meyer UA, Kindli R. 1989. Plazebos and Nozebos. Ther Umsch 46:544-54
  185. Matsunaga E, Zanger UM, Hardwick JP, Gelboin HV, Meyer UA, Gonzalez FJ. 1989. The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 28:7349-55
  186. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. 1989. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96
  187. Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M. 1989. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 45:28-33
  188. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. 1989. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45:889-904
  189. Grant DM, Lottspeich F, Meyer UA. 1989. Evidence for two closely related sozymes of arylamine N-acetyltransferase in human liver. FEBS Lett 244:203-7
  190. Grant DM, Blum M, Demierre A, Meyer UA. 1989. Nucleotide sequence of an ntronless gene for a human arylamine N- acetyltransferase related to polymorphic drug acetylation. Nucleic Acids Res 17:3978
  191. Blum M, Grant DM, Demierre A, Meyer UA. 1989. Nucleotide sequence of a full-ength cDNA for arylamine N- acetyltransferase from rabbit liver. Nucleic Acids Res 17:3589
  192. Blum M, Grant DM, Demierre A, Meyer UA. 1989. N-acetylation pharmacogenetics: A gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits. Proc Natl Acad Sci USA 86:9554-57
  193. Bargetzi MJ, Meyer UA, Birkhaeuser MH. 1989. Premenstrual exacerbations in hepatic porphyria: prevention by intermittent administration of an LH-RH agonist in combination with a gestagen. JAMA 261:864
  194. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. 1989. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 46:521-7
  195. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, et al. 1989. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264:10388-95
  196. Zanger UM, Vilbois F, Hardwick JP, Meyer UA. 1988. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27:5447-54
  197. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. 1988. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 85:8256-60
  198. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. 1988. Two mutant alleles of the human cytochrome P-450db1 gene (P4502D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85:5240-43
  199. Skoda RC, Demierre A, McBride OW, Gonzalez FJ, Meyer UA. 1988. Human microsomal xenobiotic epoxide hydrolase. Complementary DNA sequence, complementary DNA-directed expression in COS-1 cells, and chromosomal localization. J Biol Chem 263:1549-54
  200. Meyer UA, Skoda R, Zanger U, Vilbois F, and Gonzalez FJ. 1988. Genetic polymorphisms of drug metabolizing $ enzymes. In Toxicological and Immunological Aspects of Drug Metabolism and Enivronmental Chemicals, ed. RW Estabrook, E Lindenlaub, F Oesch, A Weck:229 Stuttgart, New York: F.K. Schattauer. pp 229-39
  201. Meyer UA, Catin T, Demierre A, Fonne R, Kronbach T, et al. 1988. Molecular mechanisms of the debrisoquine- and mephenytoin-polymorphisms: studies at the protein and DNA level and with circulating autoantibodies against P450bufI (db) and P450meph. In Microsomes and Drug Oxidation. London, Philadelphia: Taylor and Francis. pp 201-8
  202. Meyer UA. 1988. Arzneimittel-Interaktionen. Schweiz Monatsschr Zahnmed 98:1232
    Kronbach T, Fischer V, Meyer UA. 1988. Cyclosporine metabolism in human liver: identification of a cytochrome P- 450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43:630-5
  203. Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, et al. 1988. Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2:174-9
  204. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, et al. 1988. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:442-46
  205. Gonzalez FJ, Skoda R, Hardwig JP, Song BJ, Umeno M, et al. Human and rat debrisoquine 4-hydroxylase and ethanol- inducible P450 gene families: structure, regulation and polymorphisms. Proc. Microsomes and Drug Oxidations, Adelaide, Australia, 1988:209-15: Taylor & Francis, London, Philadelphia
  206. Gonzalez FJ, Schmid BJ, Umeno M, McBride OW, Hardwick JP, et al. 1988. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 7:79-86
  207. Gonzalez FJ, Matsunaga E, Umeno M, Kimura S, Skoda RC, et al. Structure and evolution of the polymorphic debrisoquine 4-hydroxylase genes in man and rat. Proc. Poceedings of the IInd Internat. ISSX Meeting-ISSX-88 “Xenobiotic Metabolism and Disposition”, Kobe, Japan, 1988: Taylor and Francis
  208. Fonne-Pfister R, Meyer UA. 1988. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37:3829-35
  209. Osikowska-Evers B, Dayer P, Meyer UA, Robertz GM, Eichelbaum M. 1987. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers. Clin Pharmacol Ther 41:320-5 Nebert DW, Jaiswal AK, Meyer UA, Gonzalez FJ. 1987. Human P-450 genes: evolution, regulation and possible role in carcinogenesis. Biochem Soc Trans 15:586-9
  210. Meyer UA. 1987. Polymorphisms of human drug metabolising enzymes. In Drug Metabolism – From Molecules to Man, ed. DJ Benford, JW Bridges, GG Gibson:95-105: Taylor & Francis. Number of 95-105 pp.
  211. Meier UT, Meyer UA. 1987. Genetic polymorphism of human cytochrome P450 S-mephenytoin-4-hydroxylase.
    Biochemistry 26:8466-74
  212. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA. 1987. High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O- demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32
  213. Gonzalez FJ, Matsunaga T, Nagata K, Meyer UA, Nebert DW, et al. 1987. Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 6:149-61
  214. Fonne-Pfister R, Bargetzi MJ, Meyer UA. 1987. MPTP, the neurotoxin inducing Parkinson’s disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4- hydroxylation. Biochem Biophys Res Commun 148:1144-50
  215. Fonne R, Meyer UA. 1987. Mechanisms of phenobarbital-type induction of cytochrome P-450 isozymes. Pharmacol Ther
  216. Dayer P, Kronbach T, Eichelbaum M, Meyer UA. 1987. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1′- hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol 36:4145-52
  217. Bargetzi M, Meyer UA. 1987. Porphyrie-Therapie mit Hämatin. Die gelben Hefte 4:174-81
  218. Repond C, Bulgheroni A, Meyer UA, Mayer JM, Testa B. 1986. Dual ligand binding of pyridylalkanamides to microsomal cytochrome P-450. Biochem Pharmacol 35:2233-40
  219. Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, et al. 1986. The molecular mechanisms of two common polymorphisms of drug oxidation–evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16:449-64
  220. Meyer UA. 1986. Genetic polymorphisms of human cytochromes P-450. In Porphyrins and Porphyrias, ed. Y Nordman, Colloque INSERM. Pp 101-7
  221. Meyer UA. 1986. Gedanken zur qualitativen Verbesserung der Selbstmedikation. Sozial- und Präventivmedizin 31:156-9
  222. Leeman T, Dayer P, Meyer UA. 1986. Single-dose quinidine treatment inhibits metropolol oxidation in extensive metabolizers. Eur J Clin Pharmacol 29:739-41
  223. Gut J, Meier UT, Catin T, Meyer UA. 1986. Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation. Biochem Biophys Acta 884:435-47
  224. Gut J, Catin T, Dayer P, Kronbach T, Zanger U, Meyer UA. 1986. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J Biol Chem 261:11734-43 Dayer P, Leemann T, Kupfer A, Kronbach T, Meyer UA. 1986. Stereo- and regioselectivity of hepatic oxidation in man— effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation. Eur J Clin Pharmacol 31:313-18
  225. Meyer UA, Dayer P, Gut J, Kronbach T. 1985. Studies on the molecular basis of polymorphic drug oxidation (debrisoquine/sparteine-type) in man. In Trends in Hepatology, ed. L Bianchi, W Gerok, H Popper: MTP Press.pp 81-6
  226. Meyer UA. 1985. Genetic variants of hepatic microsomal polysubstrate monooxygenases (Cytochrome P450). In
    Hepatology, ed. H Brunner, H Thaler: New York: Raven Press. pp75-8 Meyer UA. 1985. Bittere und süsse Pillen. Sandoz-Bulletin 73:4-12
    Meyer UA. 1985. Natur und Chemie und die moderne Medizin. Schweiz Med Wschr 115:750-1
  227. Meier UT, Kronbach T, Meyer UA. 1985. Assay of mephenytoin metabolism in human liver microsomes by high- performance liquid chromatography. Anal Biochem 151:286-91
  228. Meier UT, Dayer P, Male PJ, Kronbach T, Meyer UA. 1985. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phentoyped in vivo. Clin Pharmac Ther 38:488-94
  229. Dayer P, Leeman T, Gut J, Kronbach T, Kupfer A, et al. 1985. Steric configuration and polymorphic oxidation of lipophilic beta-adrenoceptor blocking agents: In vivo – in vitro correlations. Biochem Pharmacol 34:399-400
  230. Bonkovsky HL, Hauri HP, Marti U, Gasser R, Meyer UA. 1985. Cytochrome P450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. Gastroenterology 88:458- 67
  231. Minder EI, Meier PJ, Muller HK, Minder C, Meyer UA. 1984. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation. Eur J Clin Invest 14:184-9
  232. Meyer UA. 1984. The clinical pharmacology of cytochrome P450. In Proceedings of the Second Conference on Clinical Pharmacology and Therapeutics, ed. L Lemberger, MM Reidenberg. Bethesda: American Soc. Pharmacol. Exp. Therap. pp 331-41
  233. Meier PJ, Gasser R, Hauri HP, Stieger B, Meyer UA. 1984. Biosynthesis of rat liver cytochrome P450 in mitochondria associated rough endoplasmatic reticulum and in rough microsomes in vivo. J Biol Chem 259:10194-200
  234. Hirsiger H, Giger U, Meyer UA. 1984. Stimulation of DNA synthesis and mitotic activity of chick embryo hepatocytes in primary culture. Effect on induction of polysubstrate monooxygenase activity. In Vitro 20:172-82
  235. Gut J, Gasser R, Dayer P, Kronbach T, Catin T, Meyer UA. 1984. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation. FEBS Lett 173:287-90
  236. Grant DM, Lottspeich F, Meyer UA. 1984. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol
  237. Dayer P, Gasser R, Gut J, Kronbach T, Robertz GM, et al. 1984. Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)–increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers. Biochem Biophys Res Commun 125:374-80
  238. Breimer DD, Dengler HJ, Eichelbaum M, Kalow W, Meyer UA, et al. 1984. Molecular basis of polymorphic drug oxidation in man. Eur. J. Clin. Pharmacol. 27:253-7 Meyer UA, Pirovino M. 1983. Krankheiten des Hämstoffwechsels. In Therapie Innerer Krankheiten, ed. G Riecker: Springer-Verlag. pp 390-6
  239. Meyer UA, Meier P. 1983. Klinisch bedeutsame vererbte Unterschiede in der Arzneimittelwirkung. Zbl. Pharm. 122:355- 60
  240. Meyer UA, Gysling E. 1983. Unerwünschte Arzneimittel-Interaktionen. Pharma-Kritik 5:45-52
  241. Meyer UA. 1983. Hepatic porpyhrias. In Liver in Metabolic Diseases, ed. L Bianchi, W Gerok, L Landmann, K Sickinger, GA Stalder. Boston: MTP Press.pp 379-84
  242. Meyer UA. 1983. Art und Weise der Informationsbelieferung an den praktizierenden Arzt. Bulletin der Vereinigung der selbstdispensierenden Aerzte der Schweiz 14:3-8
  243. Meyer UA. 1983. Porphyrias. In Harrison’s Principles of Internal Medicine,10th ed.:533-9. New York: McGraw Hill Book Company. pp 533-9.
  244. Meier PJ, Müller HK, Dick B, Meyer UA. 1983. Hepatic Monooxygenase Activities in Subjects with a Genetic Defect in Drug Oxidation. (Debrisoquine-Polymorphism). Gastroenterology 85:682-92
  245. Giger U, Meyer UA. 1983. Effect of succinylacetone on heme and cytochrome P450 synthesis in hepatocyte culture.
    FEBS Lett 153:335-8
  246. Breimer DD, Dengler HJ, Eichelbaum M, Kalow W, Meyer u, et al. 1983. Report on the Workshop “Molecular Basis of Polymorphic Drug Oxidation in Man”. Eur J Clin Pharmacol 27:253-7
  247. Tartini R, Kappenberger L, Steinbrunn W, Meyer UA. 1982. Dangerous interaction between amiodarone and quinidine.
    Lancet 1:1327-9
  248. Minder E, Meyer UA. 1982. Pharmakogenetik in der praktischen Medizin. Pharma-Kritik 4
  249. Meyer UA, Sweeney GS. 1982. Heme synthesis and degradation: its role in predicting drug toxicity. Introduction. In Advances in Pharmacology and Therapeutics II, ed. H Yoshida, Y Hagihara, S Ebashi, Oxford, New York: Pergamon Press.
  250. Meyer UA, Meier PJ. 1982. Klinisch bedeutsame vererbte Unterschiede in der Arzneimittelwirkung. Schweiz Med Wochenschr 112:666-9
  251. Meyer UA. 1982. Effect of drugs and chemicals on -aminolevulinic acid synthase, the rate-limiting enzyme of heme synthesis. In Advances in Pharmacology and Therapeutics II, ed. H Yoshida, Y Hagihara, S Ebashi, Oxford, New York: Pergamon Press. pp 107-10
  252. Meier PJ, Fehr J, Meyer UA. 1982. Pyridoxine-responsive primary acquired sideroblastic anaemia. In vitro and in vivo effects of vitamin B6 on decreased 5-aminolaevulinate synthase activity. Scand J Haematol 29:421-4
  253. Giger U, Meyer UA. 1982. The substituted pyridines metyrapone and nicotinamide are inducers of 5-aminolevulinate synthase and cytochrome P-450 in hepatocyte culture. Biochem Pharm 31:1735-41
  254. Gasser R, Hauri HP, Meyer UA. 1982. The turnover of cytochrome P450b. FEBS Lett 147:239-42
  255. Bochsler HP, Meyer UA. 1982. Bioavailability of 3 theophylline delayed-release preparations. Comparison of theophylline concentrations in the serum and saliva in the steady state. Schweiz Med Wochenschr 112:1702-10
  256. Meyer UA. 1981. Welche Arzneimittel-Wechselwirkungen sind relevant? Aerztl. Praxis:1753-4 Meier PJ, Spycher MA, Meyer UA. 1981. Isolation and characterization of rough endoplasmic reticulum associated with mitochondria from normal rat liver. Biochim Biophys Acta 646:283-97.
    Giger U, Meyer UA. 1981. Role of heme in the induction of cytochrome P450 by phenobarbitone. Biochem J 198:321-9 Giger U, Meyer UA. 1981. Induction of delta-aminolevulinate synthase and cytochrome P-450 hemoproteins in
    hepatocyte culture. Effect of glucose and hormones. J Biol Chem 256:11182-90
  257. Denk H, Kalt R, Abdelfattach-Gad M, Meyer UA. 1981. Effect of Griseofulvin on 5-aminolevulinate synthase and on ferrochelatase in mouse liver neoplastic nodules. Cancer Res 41:1535-8
  258. Althaus FR, Meyer UA. 1981. Effects of phenobarbital, beta-naphthoflavone, dexamethasone, and formamidoxime on the turnover of inducible microsomal proteins in cultured hepatocytes. J Biol Chem 256:13079-84
  259. Sengupta C, Meyer UA, Carafoli E. 1980. Binding of dantrolene sodium to muscle intracellular membranes. FEBS Lett
  260. Meyer UA, Meier PJ, Hirsiger H, Giger U, Althaus FR. 1980. Induction of drug-metabolizing enzymes by phenobarbitone: structural and biochemical aspects. Ciba Found Symp 76:101-18
  261. Meyer UA. 1980. Zelltherapie: Gefährliches und teures Spiel mit der Hoffnung auf Wunder? Pharma-Kritik 1:81
  262. Meyer UA. 1980. Porphyrias. In Harrison’s Principle of Internal Medicine, 9th ed.:494-500. New York: McGraw Hill pp. 494-500
  263. Hirsiger H, Althaus FR, Giger U, Meyer UA. 1980. Drug-mediated induction of cytochrome P450 hemoprotein in primary chick embryo hepatocyte culture. In Microsomes, Drug Oxidations and Chemical Carcinogenesis: Academic Press.
    pp 591-4
  264. Giger U, Meyer UA. 1980. Modulation of the induction of cytochrome P450 by nutritional and hormonal factors: studies in hepatocyte culture. In Biochemistry, Biophysics and Regulation of Cytochrome P450. North-Holland: Elsevier. pp 199- 202
  265. Meyer UA, Gysling EH. 1979. Unerwünschte Arzneimittelwechselwirkung. Pharma-Kritik 1:17-24
  266. Meyer UA, Althaus FR. 1979. Drug metabolism in cultured hepatocytes from adult rats and chicken embryos. In The Liver: Aulendorf: Editio Cantor. pp 126-34
  267. Meyer UA, Althaus FR. 1979. Drug metabolism in adult rat and chick embryo hepatocytes in primary monolayer culture. In The Induction of Drug Metabolism, ed. RW Estabrook, E Lindenlaub: Stuttgart, New York: F.K. Schattauer Verlag. pp 373-83
  268. Meyer UA. 1979. Arzneimittel-Interaktionen. Schweiz Med Wochenschr 109:359-61 Meyer UA. 1979. Welche Arzneimittelwirkungen sind klinisch relevant? Internist 20:251-6
    Meyer UA. 1979. Regulation of drug metabolism – biochemical aspects. In Pharmacologie perinatale. INSERM, 89:127.
  269. Althaus FR, Sinclair JF, Sinclair P, Meyer UA. 1979. Drug mediated induction of cytochrome(s) P450 and drug metabolism in cultured hepatocytes maintained in chemically defined medium. J Biol Chem 254:2148-53
  270. Meyer UA, Schmid R. 1978. The Porphyrias. In The Metabolic Basis of Inherited Disease, ed. JB Stanbury, B Wyngaarden, DS Frederickson. New York: McGraw-Hill. pp 1166-. Meyer UA. 1978. Pharmacogenetics in the field of heme and hemoprotein synthesis. In The effect of chemicals on heme and hemoprotein metabolism. Handbook of Experimental Pharmacology, ed. WN Aldrigdge, FD Matteis, WN Aldridge, Heidelberg: Springer Verlag. pp 239-54
  271. Meyer UA. 1978. Drug sensitivity in hereditary hepatic porphyria. Human Genetics Supp. 1:71-8
  272. Meyer UA. 1978. Regulation of heme biosynthesis in hepatic and erythroid cells. In Diagnosis and Therapy of Porphyrias and Lead Intoxication, ed. M Doss:. Heidelberg: Springer Verlag.pp 3-9
  273. Meyer UA. 1978. Pharmaocgenetics in the field of heme metabolism: Drug sensitivity in hereditary heaptic porphyria. In
    Heme and Hemoproteins, ed. F DeMatteis, WN Aldrigdge Heidelberg: Springer Verlag.pp 239-55
  274. Meyer UA. 1978. Role of genetic factors in the rational use of drugs. In Clinical Pharmacology: Basic Principles of Therapeutics, ed. KL Melmon, HF Morelli. New York: Macmillan.pp 913-.
  275. Meier PJ, Spycher MA, Meyer UA. 1978. Isolation of a subfraction of rough endoplasmic reticulum closely associated with mitochondria. Evidence for its role in cytochrome P450 synthesis. Exp Cell Res 111:479-83.
  276. Meyer PJ, Spycher MA, Meyer UA. 1977. Structural and functional interaction of rough endoplasmic reticulum (RER) and mitochondria during synthesis of hepatic cytochrome P450. In Microsomes and Drug Oxidations. Oxford, New York: Pergamon Press. pp 339-46
  277. Guzelian PS, Bissell DM, Meyer UA. 1977. Drug metabolism in adult rat hepatocytes in primary monolayer culture.
    Gastroenterology 72:1232-9
  278. Meyer UA, Meier PJ, Correia MA. 1976. Interaction between mitochondria and rough endoplasmic reticulum during induction of cytochrome P450. In The Liver, R Preisig, J Bircher, P Baumgartner (eds). Aulendorf: Editio Cantor. pp 172- 178
  279. Meyer UA. 1976. Biotransformation von Arzneimitteln in der Leber: Bedeutung für die Pharmakotherapie. In Toxische Leberschäden, Medikamente und Leber, ed. L Wannagat: Stuttgart: Georg Thieme Verlag. pp 34-.
  280. Meyer UA. 1976. Arzneimittel-Interaktionen. Schweiz Med Wochenschr 106:424-6
  281. Meyer UA. 1976. Hereditary Hepatic Porphyrias – New findings on the metabolic defects. In Progress in Liver Diseases, ed. H Popper, F Schaffner: Grune and Stratton.pp 280-.
  282. McDonagh AF, Pospisil R, Meyer UA. 1976. Degradation of hepatic haem to porphyrins and oxophlorins in rats treated with 2-allyl-2-isopropylacetamide. Biochem. Soc. Trans. 4:297-8
  283. Maxwell JD, Meyer UA. 1976. Drug sensitivity in hereditary hepatic porphyria. In Porphyrins in Human Diseases, ed. M Doss:Basel: Karger.pp 1-9
  284. Maxwell JD, Meyer UA. 1976. Effect of lead on hepatic delta-aminolaevulinic acid synthetase activity in the rat: a model for drug sensitivity in intermittent acute porphyria. Eur J Clin Invest 6:373-9
  285. Meyer UA, Maxwell JD. 1975. Human and experimental porphyria: Relationship of defects in heme biosynthesis to drug idiosyncrasy. In Drugs and the Liver, ed. W Gerok, K Sickinger. Stuttgart: F.K. Schattauer Verlag. pp 201-.
  286. Meyer UA. 1975. Biosynthese von Haem. Schweiz Med Wochenschr 105:1165-8
  287. Meyer UA. 1975. Polypragmasie: Problematik der Beschränkung auf wenige Arzneimittel. Praxis, Editorial 65:529 Correia MA, Meyer UA. 1975. Apocytochrome P-450: reconstitution of functional cytochrome with hemin in vitro. Proc Natl Acad Sci U S A 72:400-4
  288. Meyer UA, Schmid R. 1974. Intermittent acute porphyria: the enzymatic defect. Res Publ Assoc Res Nerv Ment Dis
  289. Meyer UA. 1974. Intermittierend akute Porphyria: Klinische Bedeutung der verminderten Aktivität der Uroporphyrinogen I Synthetase. Schweiz. Med. Wochenschr. 104:1874-8
  290. Meyer UA. 1974. Klinische Pharmakologie – eine Herausforderung für interdisziplinäre Zusammenarbeit. Neue Zürcher Zeitung, Forschung und Technik Nr. 508:65
  291. Schacter BA, Marver HS, Meyer UA. 1973. Heme and hemoprotein catabolism during stimulation of microsomal lipid peroxidation. Drug Metab Dispos 1:286-92.
  292. Meyer UA, Schmid R. 1973. Hereditary hepatic porphyrias. Fed Proc 32:1649-55.
  293. Meyer UA. 1973. Intermittent acute porphyria. Clinical and biochemical studies of disordered heme biosynthesis. Enzyme
  294. Chapman GS, Jones AL, Meyer UA, Bissell DM. 1973. Parenchymal cells from adult rat liver in nonproliferating monolayer culture. II. Ultrastructural studies. J Cell Biol 59:735-47
  295. Bissell DM, Hammaker LE, Meyer UA. 1973. Parenchymal cells from adult rat liver in nonproliferating monolayer culture. I. Functional studies. J Cell Biol 59:722-34
  296. Strand LJ, Meyer UA, Felsher BF, Redeker AG, Marver HS. 1972. Decreased red cell uroporphyrinogen I synthetase activity in intermittent acute porphyria. Journal of Clinical Investigation 51:2530-6
  297. Schacter BA, Meyer UA, Marver HS. 1972. Hemoprotein catabolism during stimulation of microsomal lipid peroxidation.
    Biochim Biophys Acta 279:221-7.
  298. Meyer UA, Strand LJ, Doss M, Rees AC, Marver HS. 1972. Intermittent acute porphyria. Demonstration of a genetic defect in porphobilinogen metabolism. N Engl J Med 286:1277-82
  299. Meyer UA, Marver HS. 1971. Chemically induced porphyria: increased microsomal heme turnover after treatment with allylisopropylacetamide. Science 171:64-6.
  300. Meyer UA, Marver HS. 1971. Porphyrin biosynthesis. Enhancement of the fractional catabolic rate of microsomal haem in chemically induced porphyria. S Afr Med J:175-7.
  301. Froesch ER, Meyer UA, Jakob A, Labhart A. 1969. Response of adipose tissue to insulin deficiency, fasting and refeeding, inhibition and activation of lipolysis by insulin. Proc. International Congress Series No.184, pp 124-134
  302. Meyer UA, Sturzenegger V, Froesch ER. 1968. Transport and metabolism of glucose, insulin sensitivity and lipolysis of epididymal adipose tissue of alloxan-diabetic rats after prolonged incubation in vitro. Diabetologia 4:87-94
  303. Mueller J, Froesch ER, Meyer UA, Labhart A. 1967. Persistierende Störung der ACTH-Sekretion nach Operation eines Nebennierenrindenadoms bei drei Fällen von Cushing Syndrom. Schweiz. Med. Wochenschr. 97:861-5
  304. Jakob A, Meyer UA, Flury R, Ziegler WH, Labhart A, Froesch ER. 1967. The pathogenesis of tumour hypoglycaemia: blocks of hepatic glucose release and of adipose tissue lipolysis. Diabetologia 3:506-14.
  305. Froesch ER, Waldvogel M, Meyer UA, Jakob A, Labhart A. 1967. Effects of 5-methylpyrazole-3-carboxylic acid on adipose tissue. I. Inhibition of lipolysis, effects on glucose, fructose, and glycogen metabolism in vitro and comparison with insulin. Mol Pharmacol 3:429-41
  306. Froesch ER, Waldvogel M, Meyer UA, Jakob A, Labhart A. 1967. Effects of 5-methylpyrazole-3-carboxylic acid on adipose tissue. II. Antilipolytic and hypoglycemic effects in vivo. Mol Pharmacol 3:442-52
  307. Meyer UA. 1966. Metabolism of adipose tissue of normal, alloxan-diabetic and fasted-refed rats during prolonged incubation in vitro. Diabetologia 2:189-94 ( M.D.Thesis ).

download complete list of publications